Edwards Lifesciences Corporation (EW) Q4 2013 Earnings Results

Edwards Lifesciences Beats on EPS, Stock Down 1.5%

Edwards Lifesciences reported a better-than-expected EPS, indicating strong profitability. However, the stock fell by 1.5%, likely due to the lack of revenue details and forward guidance. Investors may be cautious as they await more information on future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.91	N/A	+10.04%

Management

Management commentary

Tone: Cautiously Optimistic

Management remains cautiously optimistic about future growth driven by their product offerings. However, they did not provide specific guidance for the next quarter.

Management highlighted the strong performance in their heart valve business.

They expressed confidence in their ongoing product pipeline.

No specific guidance was provided for the upcoming quarters.

Edwards Lifesciences Beats on EPS, Stock Down 1.5%

Key numbers

Management commentary

Edwards Lifesciences Corporation

More earnings this week

Edwards Lifesciences Beats on EPS, Stock Down 1.5%

Key numbers

Management commentary